- AuthorisedTherapeutic exploratory (Phase II)
Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613
This study is looking at how well two medicines, fianlimab and cemiplimab, work together to treat a type of skin cancer called melanoma. Researchers are checking how long people live after having this combination treatment and if the cancer comes back or gets worse.
For: MelanomaIreland - Active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
For: MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is comparing two drug combinations for advanced melanoma skin cancer: fianlimab plus cemiplimab, and pembrolizumab. It aims to see which is more effective, what side effects occur, and how they affect adults and teenagers.
For: MelanomaUnited States · Argentina · Australia